Hydroxypropyl-Beta-CyclodextrinHuman evidence · Panacea Bio Chem
Hydroxypropyl-beta-cyclodextrin in people
In people, hydroxypropyl-beta-cyclodextrin has shrunk a carotid plaque by more than a third in 35 days, reversed the yearly growth of coronary calcium, opened a critical coronary narrowing from 82 % to 24 % and relieved angina in nine of ten patients in a case series. Trials are running on three continents.
Plaque regression reports
| Year | Finding | Report | Detail |
|---|---|---|---|
| 2024 | Rapid carotid plaque regression | Case report, intravenous HPβCD | Carotid plaque reduced by 35.9 % on day 35 of the infusion regimen, with lower lipid and uric-acid levels and improved liver function.[1] |
| 2025 | Angina relieved, regression documented | Case series, HPβCD therapy | 18 of 20 patients with active angina (90 %) reported significant clinical improvement; objective regression of atherosclerosis in high-risk patients.[2] |
| 2025 | Better symptoms and quality of life in 12 weeks | Observational study, rectal HPβCD (Cavadex) | A high-risk group — prior heart attack, high coronary calcium, persistent angina — reported improved health, energy and cardiovascular symptoms, with angina reduced or resolved and exercise capacity enhanced.[3] |
| 2026 | Calcified plaque reversed | Multi-centre retrospective case series, high-viscosity HPβCD (Cavadex) | Coronary calcium progression reversed from +27.9 % a year to −10.5 % a year in an index case; a critical coronary stenosis fell from 82 % to 24 %; more than 90 % of symptomatic participants reported relief.[4] |
Human cells, human plaque
In blood cells from 76 patients undergoing coronary angiography, a hydroxypropyl cyclodextrin significantly reduced the monocytes' uptake of cholesterol crystals — the step that ignites the inflammasome[9]. In human atherosclerotic plaque tissue, the ring raised the oxysterols that switch on cholesterol export[10].
Registered trials
| Registry | Study | Design and status |
|---|---|---|
| ACTRN12622001377729 | Oral HPβCD in coronary artery disease | Phase 2a, Beren Therapeutics, Australia and New Zealand — completed with 10 patients (Dec 2022 – Feb 2023)[5] |
| NCT06813339 | UDP-003, a cyclodextrin built to remove 7-ketocholesterol | First-in-human, Cyclarity Therapeutics — recruiting since February 2025[6] |
| NCT04860960 | Intravenous HPβCD (Trappsol® Cyclo™) in Niemann-Pick type C1 | Phase 3, Cyclo Therapeutics[7] |
| NCT05607615 | Intravenous HPβCD in early Alzheimer's disease | Phase 2, Cyclo Therapeutics[8] |
A long human record
Hydroxypropyl-beta-cyclodextrin has been given to people for decades: intravenously as a parenteral excipient and a lipid-mobilising agent[11,12], and into the spinal fluid in Niemann-Pick disease, where it slowed neurological progression[13,14].
The person behind the resource
Bogdan Dicoias
Biochemist and inventor · Director, Panacea Bio Chem
Panacea Bio Chem's cyclodextrin research is led by Bogdan Dicoias, inventor of the Peptourbillon® formulation engine and the Lyoprester® dual-chamber cartridge. dicoias.com
“Panacea Bio Chem is not merely interested in molecules. Panacea works on the physical, chemical and technological environment surrounding them.”
Bogdan Dicoias
Trending in the field
Recent developments in the field — refreshed 2026-11-07 by Panacea Bio Chem.
- A combination nano-immunotherapy targeting cholesterol crystals and STING signaling enhanced disruption atherosclerotic plaque pathogenesis. — PubMed, 2026
- Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography. — PubMed, 2025
- Cyclodextrin: Dual Functions as a Therapeutic Agent and Nanocarrier for Regulating Cholesterol Homeostasis in Atherosclerosis. — PubMed, 2025
- Reversal of foam cell formation by removal of 7-ketocholesterol with the cyclodextrin dimer UDP-003: a new potential drug candidate to promote atherosclerotic plaque regression. — PubMed, 2025
References
- Hodgetts K, Howes L, Fang YY, Song ZM. 2-Hydroxypropyl-β-Cyclodextrin Induces Rapid Regression of Atherosclerotic Plaque and Reduces Hyperlipidaemia in Adult with Cardiovascular Disease. Cardiol Res Cardiovasc Med 2024;9:261. doi.org/10.29011/2575-7083.100261
- Hodgetts K, Roberts JC, Howes LG. Cyclodextrin Therapy for Atherosclerotic Cardiovascular Disease: A Case Series on Plaque Regression and Symptomatic Improvement. Cardiol Res Cardiovasc Med 2025;10:284. doi.org/10.29011/2575-7083.100284
- Hodgetts K. Symptomatic Improvement and Enhanced Quality of Life in Individuals with Atherosclerotic Cardiovascular Disease Following a 12-Week Self-Monitored Regimen of Rectally Administered 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): An Observational Study. Cardiol Res Cardiovasc Med 2025;10:287. doi.org/10.29011/2575-7083.100287
- Hodgetts K, Roberts J. Regression of Atherosclerotic Plaque Via High-Viscosity 2-Hydroxypropyl-β-Cyclodextrin (Cavadex): A Multi-Center Retrospective Case Series. Cardiol Res Cardiovasc Med 2026;11:292. doi.org/10.29011/2575-7083.100292
- ANZCTR ACTRN12622001377729. Safety and activity of oral HPBCD in coronary artery disease (Phase 2a). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384782
- ClinicalTrials.gov NCT06813339. Single and multiple ascending doses of UDP-003 (Cyclarity Therapeutics). clinicaltrials.gov/study/NCT06813339
- ClinicalTrials.gov NCT04860960. Intravenous Trappsol® Cyclo™ in Niemann-Pick disease type C1 (Phase 3). clinicaltrials.gov/study/NCT04860960
- ClinicalTrials.gov NCT05607615. Trappsol® Cyclo™ in early Alzheimer's disease (Phase 2). clinicaltrials.gov/study/NCT05607615
- Lübbering N, Krogmann A, Jansen F, Latz E, Nickenig G, Zimmer S. Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography. PLoS One 2025;20(12):e0338635. PMID 41396996
- Zimmer S, Grebe A, Bakke SS, Bode N, Halvorsen B, Ulas T, et al.. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016;8(333):333ra50. PMID 27053774
- Irie T, Fukunaga K, Garwood MK, Carpenter TO, Pitha J, Pitha J. Hydroxypropylcyclodextrins in parenteral use. II: Effects on transport and disposition of lipids in rabbit and humans. J Pharm Sci 1992;81(6):524-8. PMID 1522488
- Carpenter TO, Gerloczy A, Pitha J. Safety of parenteral hydroxypropyl beta-cyclodextrin. J Pharm Sci 1995;84(2):222-5. PMID 7738806
- Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, et al.. Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 2017;390(10104):1758-1768. PMID 28803710
- Hastings C, Liu B, Hurst B, Cox GF, Hrynkow S. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial. Mol Genet Metab 2022;137(4):309-319. PMID 36279795
Concept: Bogdan Dicoias · Published by Panacea Bio Chem Scientific Communications · first edition, 7 November 2026 · Evidence last searched 7 November 2026 (PubMed, ClinicalTrials.gov, ANZCTR) — every study cited here was read from its own record.
Panacea Peptides · Panacea Bio Chem · Bogdan Dicoias · Panacea Technologies — the Peptourbillon® formulation engine and the Lyoprester® cartridge are technologies invented by Bogdan Dicoias at Panacea Bio Chem.
